Biosimilars

Bring your biosimilar to market faster.

Partner with us to develop biosimilar products more quickly and cost-effectively, from clinical and operational planning to pipeline prioritization, feasibility analyses, and full-service study execution. Since 2009, IQVIA has worked on multiple biosimilars for over 30 unique reference biologicals and delivered more than 80 biosimilar studies across various therapeutic areas.

Innovative approaches to improve biosimilar studies

Advise

  • Global Clinical and Regulatory Strategy
  • Regulatory Consultations with Health Agencies
  • Innovative Approaches to Clinical Development
  • Chemistry Manufacturing and Controls and Compliance
  • Feasibility and Therapeutic Strategy
  • Pipeline Selection and Prioritization

Develop

  • Experienced Biosimilar Operations Team
  • Phase I/III Accelerated Solution
  • Phase I Site Networks
  • Regulatory Agency Support
  • Multisource Comparator Access
  • Q2 Biomarker Development and Lab Services
  • Clinical Development Operating Model
  • Investigator and Patient Best Practices

Commercialize

  • Commercial Strategy and Integrated Launch Planning
  • Integrated Market Access
  • Medical Affairs
  • Medical Communications / Marketing
  • Commercial Infrastructure and Oversight
  • Payer Engagement Services
  • Performance Tracking
  • Pharmacovigilance / Risk Management

The power of IQVIA Connected Intelligence™

Tap into the power of the IQVIA Connected Intelligence™ to help achieve study outcomes and bring biosimilar drugs to market faster.

  • Analysis of multiple data sources to optimize biosimilar drug development.
  • Predictive modeling and data analytics to enhance country mix, select the best sites, and augment patient enrollment.
  • Proactive, independent feasibility analyses to inform strategy.
  • Transformative technology that hastens study timelines through real-time access to operation-critical information.

Solutions you may be interested in

Contact Us